Terms: = Prostate cancer AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL
4908 results:
1. CDK9 inhibition activates innate immune response through viral mimicry.
Yalala S; Gondane A; Poulose N; Liang J; Mills IG; Itkonen HM
FASEB J; 2024 Apr; 38(8):e23628. PubMed ID: 38661032
[TBL] [Abstract] [Full Text] [Related]
2. [Application of 1470 nm semiconductor laser in the treatment of benign prostatic hyperplasia in ultra-aged patients].
Wu D; Yi XM; Wei HX; Zhang KX; Shi CJ; Shi XQ; Xu ZY; Fu D
Zhonghua Nan Ke Xue; 2023 Sep; 29(9):831-836. PubMed ID: 38639597
[TBL] [Abstract] [Full Text] [Related]
3. Discovery of the First-in-Class G9a/GLP PROTAC Degrader.
Velez J; Han Y; Yim H; Yang P; Deng Z; Park KS; Kabir M; Kaniskan HÜ; Xiong Y; Jin J
J Med Chem; 2024 Apr; 67(8):6397-6409. PubMed ID: 38602846
[TBL] [Abstract] [Full Text] [Related]
4. A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients.
Lilly MB; Wu C; Ke Y; Chen WP; Soloff AC; Armeson K; Yokoyama NN; Li X; Song L; Yuan Y; McLaren CE; Zi X
Clin Transl Med; 2024 Mar; 14(3):e1627. PubMed ID: 38515274
[TBL] [Abstract] [Full Text] [Related]
5. Neighborhood Deprivation, Race and Ethnicity, and prostate cancer Outcomes Across California Health Care Systems.
Wadhwa A; Roscoe C; Duran EA; Kwan L; Haroldsen CL; Shelton JB; Cullen J; Knudsen BS; Rettig MB; Pyarajan S; Nickols NG; Maxwell KN; Yamoah K; Rose BS; Rebbeck TR; Iyer HS; Garraway IP
JAMA Netw Open; 2024 Mar; 7(3):e242852. PubMed ID: 38502125
[TBL] [Abstract] [Full Text] [Related]
6. Compliance With NCCN Guidelines for Evaluation and Treatment of Anemia Among Patients With Solid Tumors.
Hufnagel DH; Bos LM; Brown AJ; Prescott LS
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38489926
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic Performance of RECIP 1.0 Based on [
Hartrampf PE; Hüttmann T; Seitz AK; Kübler H; Serfling SE; Higuchi T; Schlötelburg W; Michalski K; Gafita A; Rowe SP; Pomper MG; Buck AK; Werner RA
J Nucl Med; 2024 Apr; 65(4):560-565. PubMed ID: 38453363
[TBL] [Abstract] [Full Text] [Related]
8. Combination of navitoclax (Bcl-2 and Bcl-xL inhibitor) and Debio-0932 (Hsp90 inhibitor) suppresses the viability of prostate cancer cells via induction of apoptotic signaling pathway.
Asdemir A; Özgür A
Med Oncol; 2024 Mar; 41(4):83. PubMed ID: 38436810
[TBL] [Abstract] [Full Text] [Related]
9. A phase 2 pilot study of water irrigation after transurethral resection of bladder tumor (WATIP) demonstrating safety, feasibility and activity.
Li M; Nandurkar R; Toniolo J; Davis ID; Sengupta S
World J Urol; 2024 Mar; 42(1):115. PubMed ID: 38436768
[TBL] [Abstract] [Full Text] [Related]
10. A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.
Falchook GS; Reeves J; Gandhi S; Spigel DR; Arrowsmith E; George DJ; Karlix J; Pouliot G; Hattersley MM; Gangl ET; James GD; Thompson J; Russell DL; Patel B; Kumar R; Lim E
Cancer Immunol Immunother; 2024 Mar; 73(4):72. PubMed ID: 38430405
[TBL] [Abstract] [Full Text] [Related]
11. Combining magnetic resonance imaging with a multi-ancestry polygenic risk score to improve identification of clinically significant prostate cancer.
Plym A; Madueke I; Naik S; Isabelle M; Conti DV; Haiman CA; Penney KL; Mucci LA; Khorasani R; Kibel AS
JNCI Cancer Spectr; 2024 Feb; 8(2):. PubMed ID: 38429995
[TBL] [Abstract] [Full Text] [Related]
12. Single-Time-Point Renal Dosimetry Using Nonlinear Mixed-Effects Modeling and Population-Based Model Selection in [
Hardiansyah D; Yousefzadeh-Nowshahr E; Kind F; Beer AJ; Ruf J; Glatting G; Mix M
J Nucl Med; 2024 Apr; 65(4):566-572. PubMed ID: 38423787
[TBL] [Abstract] [Full Text] [Related]
13. Development and Preclinical Evaluation of [
El Fakiri M; Ayada N; Müller M; Hvass L; Gamzov TH; Clausen AS; Geis NM; Steinacker N; Hansson E; Lindegren S; Aneheim E; Jensen H; Eder AC; Jensen AI; Poulie CBM; Kjaer A; Eder M; Herth MM
J Nucl Med; 2024 Apr; 65(4):593-599. PubMed ID: 38423784
[TBL] [Abstract] [Full Text] [Related]
14. Correlation between Selenium and Zinc Levels and Survival among prostate cancer Patients.
Pietrzak S; Marciniak W; Derkacz R; Matuszczak M; Kiljańczyk A; Baszuk P; Bryśkiewicz M; Sikorski A; Gronwald J; Słojewski M; Cybulski C; Gołąb A; Huzarski T; Dębniak T; Lener MR; Jakubowska A; Kluz T; Scott RJ; Lubiński J
Nutrients; 2024 Feb; 16(4):. PubMed ID: 38398851
[TBL] [Abstract] [Full Text] [Related]
15. Synthesis and Preclinical Evaluation of Two Novel
Verena A; Merkens H; Chen CC; Chapple DE; Wang L; Bendre S; Wong AAWL; Bénard F; Lin KS
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398552
[TBL] [Abstract] [Full Text] [Related]
16. Harvesting the Power of Green Synthesis: Gold Nanoparticles Tailored for prostate cancer Therapy.
Oliveira M; Sousa A; Sá S; Soares S; Pereira AC; Rocha AC; Pais P; Ferreira D; Almeida C; Luís C; Lima C; Almeida F; Gestoso Á; Duarte MC; Barata P; Martins-Mendes D; Baylina P; Pereira CF; Fernandes R
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396953
[TBL] [Abstract] [Full Text] [Related]
17. The prostate-specific membrane antigen holds potential as a vascular target for endogenous radiotherapy with [
Heesch A; Florea A; Maurer J; Habib P; Werth LS; Hansen T; Stickeler E; Sahnoun SEM; Mottaghy FM; Morgenroth A
Breast Cancer Res; 2024 Feb; 26(1):30. PubMed ID: 38378689
[TBL] [Abstract] [Full Text] [Related]
18. A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant prostate cancer.
Boiarsky D; Gulhan DC; Savignano H; Lakshminarayanan G; McClure HM; Silver R; Hirsch MS; Sholl LM; Choudhury AD; Ananda G; Park PJ; Tewari AK; Berchuck JE
Clin Genitourin Cancer; 2024 Apr; 22(2):558-568.e3. PubMed ID: 38342659
[TBL] [Abstract] [Full Text] [Related]
19. Helicobacter hepaticus and Helicobacter bilis in liver and biliary cancers from ATBC and PLCO.
Murphy G; Freedman ND; Abnet CC; Albanes D; Cross AJ; Huang WY; Koshiol J; McGlynn K; Parisi D; Männistö S; Weinstein SJ; Waterboer T; Butt J
Helicobacter; 2024; 29(1):e13053. PubMed ID: 38332674
[TBL] [Abstract] [Full Text] [Related]
20. Functional Outcomes After Localized prostate cancer Treatment.
Al Hussein Al Awamlh B; Wallis CJD; Penson DF; Huang LC; Zhao Z; Conwill R; Talwar R; Morgans AK; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; O'Neil BB; Koyama T; Hoffman KE; Barocas DA
JAMA; 2024 Jan; 331(4):302-317. PubMed ID: 38261043
[TBL] [Abstract] [Full Text] [Related]
[Next]
